331 related articles for article (PubMed ID: 25951739)
1. Genetic tests to identify risk for breast cancer.
Lynch JA; Venne V; Berse B
Semin Oncol Nurs; 2015 May; 31(2):100-7. PubMed ID: 25951739
[TBL] [Abstract][Full Text] [Related]
2. Molecular diagnostic testing in breast cancer.
Berse B; Lynch JA
Semin Oncol Nurs; 2015 May; 31(2):108-21. PubMed ID: 25951740
[TBL] [Abstract][Full Text] [Related]
3. Risk assessment for hereditary breast cancer: BRCA1 and BRCA2.
Seenandan-Sookdeo KA; Sawatzky JA
Can Oncol Nurs J; 2010; 20(3):107-15. PubMed ID: 20812602
[TBL] [Abstract][Full Text] [Related]
4. Genetic risk assessment for breast and gynecological malignancies.
Profato JL; Arun BK
Curr Opin Obstet Gynecol; 2015 Feb; 27(1):1-5. PubMed ID: 25502427
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Risk Prediction Models: Challenges in Clinical Application.
Paquin M; Fasolino T; Steck MB
Clin J Oncol Nurs; 2019 Jun; 23(3):256-259. PubMed ID: 31099796
[TBL] [Abstract][Full Text] [Related]
6. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
7. Hereditary Breast and Hereditary Ovarian Cancer: Implications for the Oncology Nurse.
Beamer LC
Semin Oncol Nurs; 2019 Feb; 35(1):47-57. PubMed ID: 30711354
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer risk associated with CHEK2 mutations.
Mahon SM
Oncol Nurs Forum; 2014 Nov; 41(6):692-4. PubMed ID: 25355026
[TBL] [Abstract][Full Text] [Related]
9. "Decoding hereditary breast cancer" benefits and questions from multigene panel testing.
Colas C; Golmard L; de Pauw A; Caputo SM; Stoppa-Lyonnet D
Breast; 2019 Jun; 45():29-35. PubMed ID: 30822622
[TBL] [Abstract][Full Text] [Related]
10. An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Piccinin C; Panchal S; Watkins N; Kim RH
Expert Rev Anticancer Ther; 2019 Sep; 19(9):787-801. PubMed ID: 31469018
[No Abstract] [Full Text] [Related]
11. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
12. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment.
Kurian AW; Kingham KE; Ford JM
Curr Opin Obstet Gynecol; 2015 Feb; 27(1):23-33. PubMed ID: 25502425
[TBL] [Abstract][Full Text] [Related]
14. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
[TBL] [Abstract][Full Text] [Related]
15. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
[TBL] [Abstract][Full Text] [Related]
16. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
[TBL] [Abstract][Full Text] [Related]
17. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
18. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
19. Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan.
Bando H
Breast Cancer; 2014 Nov; 21(6):656-63. PubMed ID: 23754181
[TBL] [Abstract][Full Text] [Related]
20. A new paradigm of genetic testing for hereditary breast/ovarian cancers.
Kwong A; Chen JW; Shin VY
Hong Kong Med J; 2016 Apr; 22(2):171-7. PubMed ID: 26980575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
